These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1093668)

  • 1. Comparison of adriamycin (NSC-123127) and 5-fluorouracil (NSC-19893) in advanced prostatic cancer.
    DeWys WD
    Cancer Chemother Rep; 1975; 59(1):215-7. PubMed ID: 1093668
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer--progress report.
    DeWys WD; Bauer M; Colsky J; Cooper RA; Creech R; Carbone PP
    Cancer Treat Rep; 1977; 61(2):325-8. PubMed ID: 326401
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response.
    DeWys WD; Begg CB; Brodovsky H; Creech R; Khandekar J
    Prostate; 1983; 4(1):1-11. PubMed ID: 6340081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report.
    Eagan RT; Utz DC; Myers RP; Furlow WL
    Cancer Chemother Rep; 1975; 59(1):203-7. PubMed ID: 1093666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
    Eagan RT; Hahn RG; Myers RP
    Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515
    [No Abstract]   [Full Text] [Related]  

  • 6. Initial chemotherapeutic trials in patients with inoperable or recurrent cancer of the prostate.
    Tejada F; Cohen MH
    Cancer Chemother Rep; 1975; 59(1):243-9. PubMed ID: 1131804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
    Merrin C; Etra W; Wajsman Z; Baumgartner G; Murphy G
    J Urol; 1976 Jan; 115(1):86-8. PubMed ID: 1107604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
    Collier D; Soloway MS
    Urology; 1976 Nov; 8(5):459-64. PubMed ID: 982733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of 5-fluorouracil (NSC-19893), adriamycin (NSC-123127), and methotrexate (NSC-740) in lung adenocarcinoma.
    Lowitz BB
    Cancer Treat Rep; 1976 May; 60(5):623-4. PubMed ID: 991153
    [No Abstract]   [Full Text] [Related]  

  • 10. Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.
    Yagoda A
    Cancer; 1973 Nov; 32(5):1131-40. PubMed ID: 4271302
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
    Citrin DL; Elson P; DeWys WD
    Cancer; 1984 Jul; 54(1):13-7. PubMed ID: 6372984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer.
    Frytak S; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(2 Pt 1):405-9. PubMed ID: 1097099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adriamycin (NSC-123127) plus 5-fluorouracil (NSC-19893): a phase I study.
    Tranum BL; Stephens RL; Lehane DE; Hoogstraten B; Lane M; Haut A
    Cancer Chemother Rep; 1975; 59(6):1163-5. PubMed ID: 769959
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors.
    Drago JR; Goldman LB; Maurer RE; Gershwin ME; Eckels DD
    Invest Urol; 1979 Nov; 17(3):203-6. PubMed ID: 500317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with methotrexate (NSC-740), adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and 5-fluorouracil (NSC19893) for adult solid tumors.
    Stephens RL; Hoogstraten B
    Cancer Chemother Rep; 1974; 58(6):943-5. PubMed ID: 4614901
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of 5-fluorouracil and adriamycin on heterotransplantation of Noble rat prostatic tumors in congenitally athymic (nude) mice.
    Drago JR; Maurer RE; Gershwin ME; Eckels D; Palmer JM
    Cancer; 1979 Aug; 44(2):424-30. PubMed ID: 476560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chemotherapy of prostatic adenocarcinoma.
    Torti FM; Carter SK
    Ann Intern Med; 1980 May; 92(5):681-9. PubMed ID: 6992675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
    Burk K; Gropp C; Rodeck G
    Urologe A; 1983 Sep; 22 Suppl():347-9. PubMed ID: 6415885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.
    Haller DG; Woolley PV; Macdonald JS; Smith LF; Schein PS
    Cancer Treat Rep; 1978 Apr; 62(4):563-5. PubMed ID: 350394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
    Block NL; Camuzzi F; Stover B; Claflin A; Troner M; Politano VA
    Trans Am Assoc Genitourin Surg; 1978; 70():57-9. PubMed ID: 753023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.